Pall Life Sciences is now part of Cytiva!
Like you, we are eager to touch down in Boston for the BIO convention.
Together, let’s explore the possibilities for manufacturing therapies and vaccines.
June 5-8, 2023 | BIO International | Boston, MA | Booth 664
Refining strategies for success
Discover how Cytiva supports the rapidly changing biopharma ecosystem and the ever-advancing future of therapeutics.
Speed. Innovation. Efficiency. Whatever your strategy, let’s combine our strengths with yours to bring better medicines to life.
Meet the team
After learning from a global pandemic, biopharma is evolving to embrace innovation and deliver the next wave of life-saving diagnostics vaccines, and therapies. Join the evolution as we work through a series of key advances to ensure manufacturing resilience.
Book a meeting with our leaders to discuss how we at Cytiva can help you gain speed, enhance efficiency, and realize flexibility.
Emmanuel Ligner
President and CEO, Cytiva
Explore the possibilities with Emmanuel
Whatever your molecule, market, or challenges, Cytiva has the collaborative spirit to drive more agile manufacturing and innovation, supported by thorough training and development.
No one can do it alone. Let’s talk about what we can achieve together.
Emmanuel Abate
President Genomic Medicine, Cytiva
Increase the development speed of future therapies with Emmanuel Abate
Let’s collaborate to better serve the scientific community working on the next medical breakthrough. As our Genomic Medicine business leader, access insights from Emmanuel’s deep understanding for nucleic acids, viral vectors, cell therapy, and mRNA strategies.
Sven Frie
GM, Commercial Enterprise Solutions, Cytiva
Accelerate manufacturing with Sven.
Access insights about manufacturing options that could help you devise the right strategy to adjust and adapt to demand.
Identify a flexible manufacturing solution to increase the speed of your molecule’s journey.
Scott Ripley
GM, Nucleic Acid Therapeutics, Cytiva
Advance mRNA-based therapies with Scott.
Nucleic acid–based therapeutics – including mRNA, oligonucleotides, and viral expression constructs – are emerging as a conventional segment in drug development, as are cell and gene therapies.
Discover how novel therapies and vaccines are transforming global healthcare.
Jon Van Pelt
GM, BioProcess Single-use and Enterprise Solutions, Cytiva
Discover proven, single-use manufacturing backed by service and expertise with Jon.
Gain speed and flexibility for localized production with manufacturing solutions from cell to purified product.
Explore recent developments in modular manufacturing.
Silke Fetzer
VP, Commercial Sales, Cytiva
Build momentum with Silke.
We don’t bring drugs to market the way we used to, and therapies get to patients in evermore personalized ways. Discuss new approaches to your drug development, manufacturing, and delivery.
Enhance clarity and collaboration around goals for the public good.
Contact us to request a meeting at BIO
Privacy | Terms | Trademarks | Legal | Contact
© 2023 Cytiva